MA37721A1 - Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide - Google Patents

Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide

Info

Publication number
MA37721A1
MA37721A1 MA37721A MA37721A MA37721A1 MA 37721 A1 MA37721 A1 MA 37721A1 MA 37721 A MA37721 A MA 37721A MA 37721 A MA37721 A MA 37721A MA 37721 A1 MA37721 A1 MA 37721A1
Authority
MA
Morocco
Prior art keywords
oxo
oxazolidin
chloro
morpholinyl
phenyl
Prior art date
Application number
MA37721A
Other languages
Arabic (ar)
English (en)
Other versions
MA37721B1 (fr
Inventor
Klaus Benke
Heike Neumann
Wolfgang Mück
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA37721A1 publication Critical patent/MA37721A1/fr
Publication of MA37721B1 publication Critical patent/MA37721B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des formes pharmaceutiques solides, pouvant être administrées par voie orale, contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide (rivaroxaban, principe actif (i)), caractérisées en ce qu'une proportion du principe actif (i) est libérée rapidement et en ce qu'une autre proportion est libérée de manière contrôlée (modifiée, retardée, ralentie). L'invention concerne également des procédés de production de ces formes pharmaceutiques, ainsi que leur application en tant que médicament et leur utilisation pour la prophylaxie, la prophylaxie secondaire ou le traitement de maladies.
MA37721A 2012-07-03 2014-12-31 Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide MA37721B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12174797 2012-07-03
PCT/EP2013/063590 WO2014005934A1 (fr) 2012-07-03 2013-06-28 Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide

Publications (2)

Publication Number Publication Date
MA37721A1 true MA37721A1 (fr) 2016-05-31
MA37721B1 MA37721B1 (fr) 2016-12-30

Family

ID=48782297

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37721A MA37721B1 (fr) 2012-07-03 2014-12-31 Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide

Country Status (33)

Country Link
US (2) US20140010876A1 (fr)
EP (1) EP2869814B1 (fr)
JP (1) JP6166781B2 (fr)
KR (1) KR20150027284A (fr)
CN (1) CN104582684A (fr)
AP (1) AP3756A (fr)
AR (1) AR091621A1 (fr)
AU (1) AU2013286068A1 (fr)
BR (1) BR112015000043A2 (fr)
CA (1) CA2878123A1 (fr)
CL (1) CL2015000002A1 (fr)
CO (1) CO7240379A2 (fr)
CR (1) CR20150001A (fr)
CU (1) CU20140152A7 (fr)
DO (1) DOP2015000001A (fr)
EA (1) EA025016B1 (fr)
EC (1) ECSP14033581A (fr)
ES (1) ES2574627T3 (fr)
GT (1) GT201400306A (fr)
HK (1) HK1209635A1 (fr)
IL (1) IL236455A0 (fr)
IN (1) IN2014DN11066A (fr)
MA (1) MA37721B1 (fr)
MX (1) MX2015000053A (fr)
NZ (1) NZ703733A (fr)
PE (1) PE20150189A1 (fr)
PH (1) PH12014502833A1 (fr)
SG (1) SG11201408420YA (fr)
TN (1) TN2014000541A1 (fr)
TW (1) TW201414508A (fr)
UY (1) UY34856A (fr)
WO (1) WO2014005934A1 (fr)
ZA (1) ZA201500759B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
EP4134131A1 (fr) * 2016-02-23 2023-02-15 Morgandane Scientific, LLC Méthode de traitement de patients auxquels sont administrés conjointement un inhibiteur du facteur xa et du vérapamil
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
WO2020020790A1 (fr) * 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale
EP3826627B1 (fr) * 2018-07-24 2023-10-18 Bayer Aktiengesellschaft Forme d'administration pharmaceutique applicable par voie orale à libération modifiée
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
JP7641098B2 (ja) * 2019-08-30 2025-03-06 日本ジェネリック株式会社 リバーロキサバン含有錠剤
JP7465157B2 (ja) * 2020-06-15 2024-04-10 沢井製薬株式会社 リバーロキサバン含有口腔内崩壊錠の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
HK1046638B (zh) * 1998-06-03 2006-02-24 阿尔扎有限公司 提供药物长效治疗的方法和装置
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
CA2729979A1 (fr) * 2008-07-08 2010-01-14 Ratiopharm Gmbh Compositions pharmaceutiques comprenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
JP2013533241A (ja) * 2010-06-22 2013-08-22 ティダブリューアイ・ファーマシューティカルズ・インコーポレイテッド 食物効果が減少した制御放出組成物

Also Published As

Publication number Publication date
CU20140152A7 (es) 2015-10-27
CO7240379A2 (es) 2015-04-17
EA025016B1 (ru) 2016-11-30
US20150125527A1 (en) 2015-05-07
AU2013286068A1 (en) 2015-01-29
CA2878123A1 (fr) 2014-01-09
TW201414508A (zh) 2014-04-16
DOP2015000001A (es) 2015-07-15
CN104582684A (zh) 2015-04-29
TN2014000541A1 (en) 2016-03-30
JP2015521648A (ja) 2015-07-30
AP2015008208A0 (en) 2015-01-31
AP3756A (en) 2016-07-31
AR091621A1 (es) 2015-02-18
ES2574627T3 (es) 2016-06-21
PH12014502833A1 (en) 2015-02-02
ZA201500759B (en) 2017-11-29
EP2869814A1 (fr) 2015-05-13
SG11201408420YA (en) 2015-01-29
MX2015000053A (es) 2015-04-10
UY34856A (es) 2013-12-31
KR20150027284A (ko) 2015-03-11
US20140010876A1 (en) 2014-01-09
HK1209635A1 (en) 2016-04-08
MA37721B1 (fr) 2016-12-30
WO2014005934A1 (fr) 2014-01-09
EA201590142A1 (ru) 2015-06-30
PE20150189A1 (es) 2015-01-31
IL236455A0 (en) 2015-02-26
JP6166781B2 (ja) 2017-07-19
BR112015000043A2 (pt) 2017-06-27
NZ703733A (en) 2016-12-23
IN2014DN11066A (fr) 2015-09-25
ECSP14033581A (es) 2015-12-31
GT201400306A (es) 2015-08-25
CR20150001A (es) 2015-02-06
EP2869814B1 (fr) 2016-04-06
CL2015000002A1 (es) 2015-05-29

Similar Documents

Publication Publication Date Title
MA37721A1 (fr) Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide
MY143999A (en) Solid, modified-release pharmaceutical dosage forms which can be administered orally
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ECSP088339A (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201590847A1 (ru) Новые ингибиторы rock
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
UA119034C2 (uk) Агоністи рецептора окситоцину
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
ATE440839T1 (de) Aminoacyl-prodrug derivate und arzneimittel zur behandlung von thromboembolischen erkrankungen
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
WO2012080184A3 (fr) Compositions pharmaceutiques liquides administrables par voie orale contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyle)-phényle]-1,3-oxazolidin-5-yle}-méthyle)-2-thiophène carboxamide
RU2012136190A (ru) Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента
EA201991359A1 (ru) Фармацевтические лекарственные формы
EA201200799A1 (ru) Гепатопротекторное средство
EA201992816A1 (ru) Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения
RU2012137061A (ru) Фармацевтические композиции, содержащие s-амлодипина никотинат и их применение в лечении цереброваскулярных нарушений
EA201650010A3 (ru) Фармацевтическая композиция на основе 5-этокси-2-(2-(морфолино)-этилтио) бензимидазола дигидрохлорида и/или основания